NeoImmuneTech, a company specialising in T cell-focused therapeutics, has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its NT-I7 (efineptakin alfa) (rhIL-7-hyFc), for the treatment of pancreatic cancer.
The European Medicines Agency (EMA) has validated for review a Type II variation application for Pfizer and Astellas Pharma’s PADCEV (enfortumab vedotin) with KEYTRUDA (pembrolizumab) as first-line therapy option for locally advanced or metastatic urothelial cancer (la/mUC).
UroGen Pharma has submitted the Chemistry, Manufacturing, and Controls (CMC) section of the new drug application (NDA) to the US Food and Drug Administration (FDA) for UGN-102, to treat urothelial cancers.
The American Society for Transplantation and Cellular Therapy (ASTCT), the Association of Community Cancer Centers (ACCC) and the Association of American Cancer Institutes (AACI) have launched the RECUR initiative to improve patient access to CAR T therapy.
CARsgen Therapeutics has announced that its autologous CAR T-cell product candidate, CT011, received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) in China.
GENESIS Pharma has entered into an exclusive distribution agreement with Deciphera Pharmaceuticals for the marketing of Ripretinib in 14 European Union (EU) markets in Central and Eastern Europe.
Chinese biotechnology company GenFleet Therapeutics has received the US Food and Drug Administration (FDA) designations for its drug candidate SLS009 (GFH009).
Clinical-stage immunobiology company Simcha Therapeutics has signed a licence and option agreement with Johnson & Johnson subsidiary Janssen Biotech for new decoy-resistant IL-18 (DR-18).
Eli Lilly and Company has concluded the acquisition of all outstanding shares of radiopharmaceutical company POINT Biopharma in a deal valued at nearly $1.4bn.
The US Food and Drug Administration (FDA) has granted priority review to Daiichi Sankyo and Merck’s biologics license application (BLA) for patritumab deruxtecan, to potentially treat non-small cell lung cancer (NSCLC) in adults.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.